Back

Sodium-glucose cotransporter 2 inhibitor Dapagliflozin reduces systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity

13 May 2024 (09:00 - 09:45)
Organised by: Logo
Congress Presentation Part of: Cardiovascular disease in special populations - cardio-oncology (1) Cardio-Oncology HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Nicola Maurea

National Cancer Institute G.Pascale Foundation IRCCS, Naples (Italy)

7 More presentations in this session

Presentation thumbnail
Cardiac manifestations in patients with systemic sclerosis
Associate Professor V. Stoickov (Niska Banja, RS)
Abstract Slides Video
Presentation thumbnail
Association of pre-existing cardiovascular disease with administration of fluoropyrimidine chemotherapy in patients with gastrointestinal malignancies
Doctor A. Abiodun (London, GB)
Abstract Slides Video
Presentation thumbnail
Patients with non-Hodgkin's lymphoma treated with CAR T-cell therapy are at risk of impaired left ventricular function
Miss E. Polomski (Leiden, NL)
Abstract Slides Video
Presentation thumbnail
Fructose exacerbates anthracycline and HER-2 blocking agent mediated cardiotoxicity through NLRP3 and MyD88 mediated pathways: new roles of sweeteners in cardio-oncology
Doctor V. Quagliariello (Naples, IT)
Abstract Slides Video
Presentation thumbnail
The risks of continuing trastuzumab treatment in HER-2 positive breast cancer after the development of asymptomatic left ventricular dysfunction
Doctor M. Dominique Joseph (Port-au-Prince, HT)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular disease in special populations - cardio-oncology (1)

The Event

Event poster

Heart Failure 2024

13 May 2024 09:00 CET
You may be interested in
thumbnail
Congress Presentation
MyD-88/NLRP-3 inhibition by dapagliflozin protects against anthracycline and trastuzumab cardiotoxicity in preclinical models
thumbnail
Congress Presentation
Dapagliflozin in primary prevention of cardiotoxicity induced by anthracycline-trastuzumab therapy through activation of pAMPK and inhibition of MyD88 and NLRP-3
thumbnail
Congress Presentation
SGLT2 i Dapagliflozin reduces NF-kB expression in heart and kydneys of preclinical models exposed to doxorubicin through MYd-88 and NLRP3 pathways: an hystological study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources